Skip to content
ADHD Is Misunderstood in Women, New Report FindsNew research from Understood.org, a leading nonprofit for people with learning and thinking differences, finds there is an urgent, unmet need of women with ADHD. The report, titled "Missed, Misread, and Misdiagnosed: Current State of Women With ADHD," notes that for decades, ADHD was wrongly considered a "boy's disorder," and women were misdiagnosed with conditions…
Fueled by Smart Safety Glasses, Innovative Eyewear Posts 63 Percent Revenue Growth in 2025MIAMI—Innovative Eyewear Inc., (NASDAQ: LUCYW), the developer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has announced its full year 2025 financial results, demonstrating net revenue for the year ended December 31, 2025, of approximately $2.67 million, an increase of $1.03 million or 63 percent from the prior-year period.…
Fueled by Smart Safety Glasses, Innovative Eyewear Posts 63 Percent Revenue Growth in 2025MIAMI—Innovative Eyewear Inc., (NASDAQ: LUCYW), the developer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has announced its full year 2025 financial results, demonstrating net revenue for the year ended December 31, 2025, of approximately $2.67 million, an increase of $1.03 million or 63 percent from the prior-year period.…
Early Bird Registration for Optometry’s Meeting in Phoenix Ends March 31PHOENIX—Early bird registration for Optometry’s Meeting, a premier annual event for members of both the American Optometric Association and the American Optometric Student Association, ends on March 31, organizers have announced on the event homepage. Scheduled for June 17-20, 2026, in Phoenix, Ariz., Optometry's Meeting offers four days of professional advancement, bringing together doctors, paraoptometrics,…
Aurion Biotech Appoints Marjan Farid, MD, as Medical Advisory Board ChairSEATTLE, CAMBRIDGE, Mass., and TOKYO—Aurion Biotech, Inc., a commercial-stage regenerative cell therapy company that Alcon acquired a majority interest of in March 2025, has announced the appointment of Marjan Farid, MD, as the chair of its medical advisory board.
Qlaris Bio Appoints Fred Guerard, PharmD, as President and CEODEDHAM, Mass.—Qlaris Bio, Inc., a clinical-stage biotechnology company developing first-in-class therapies for glaucoma including a novel vasodilatory topical ATP-sensitive potassium channel modulator called QLS-111, has announced the appointment of Fred Guerard, PharmD, as its new president and CEO, effective March 1, 2026. The company said he has also joined its board of directors. Dr. Guerard…
